PTP1B deregulation can play a strategic role in linking resistance to insulin and leptin, neuronal stress, and inflammation; therefore, PTP1B inhibition could provide a novel disease-modifying strategy for the treatment of AD [83]. This evidence concerns the gene LEP and Alzheimer disease.